Figure 3

Comparison of the distribution of prescriptions in 1017 patients with COPD. SABA Short-acting beta-agonist, SAMA Short-acting muscarinic receptor agonist, LAMA Long-acting muscarinic receptor agonist, LABA Long-acting beta-agonist, ICS Inhaled corticosteroids, Triple, LAMA + LABA + ICS.